{"id":"captopril-hydrochlorothiazide","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Cough"},{"rate":"5-10","effect":"Dizziness"},{"rate":"2-5","effect":"Hyperkalemia"},{"rate":"5-10","effect":"Hypokalemia"},{"rate":"5-10","effect":"Hypotension"},{"rate":"0.1-0.5","effect":"Angioedema"},{"rate":"2-5","effect":"Rash"}]},"_chembl":null,"_dailymed":{"setId":"0ea90fd4-0da6-4ad2-ab83-6cfbe0ae515e","title":"CAPTOPRIL AND HYDROCHLOROTHIAZIDE TABLET [RISING PHARMA HOLDINGS, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Captopril blocks ACE, preventing conversion of angiotensin I to angiotensin II, which reduces vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that increases urinary sodium and water excretion, lowering blood volume and pressure. Together, they provide complementary antihypertensive effects.","oneSentence":"This combination reduces blood pressure by inhibiting angiotensin-converting enzyme (ACE) to dilate blood vessels and promoting sodium and water excretion through diuretic action.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:29:45.954Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure"}]},"trialDetails":[{"nctId":"NCT03179163","phase":"PHASE1, PHASE2","title":"Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans","status":"TERMINATED","sponsor":"Penn State University","startDate":"2016-07-20","conditions":"Hypertension,Essential","enrollment":10},{"nctId":"NCT04964050","phase":"PHASE1","title":"A Bioequivalence Study Between Capozide Versus ACE-Hemmer-ratiopharm in Healthy Adult Participants Under Fasting Conditions","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2022-04-21","conditions":"Healthy Volunteers","enrollment":""},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT04371874","phase":"NA","title":"The Standardized Management of Hypertension in Rural Shaanxi","status":"COMPLETED","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2014-01","conditions":"Hypertension","enrollment":1210},{"nctId":"NCT03147092","phase":"EARLY_PHASE1","title":"Matão Controlling Hypertension (MatCH Study): Rationale and Design","status":"UNKNOWN","sponsor":"Centro Neurológico de Pesquisa e Reabiitação, Brazil","startDate":"2018-02-01","conditions":"Hypertension, Blood Pressure","enrollment":15000},{"nctId":"NCT00223717","phase":"PHASE1","title":"Treatment of Supine Hypertension in Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2001-01","conditions":"Hypertension","enrollment":152},{"nctId":"NCT02217852","phase":"PHASE4","title":"Treatment of Hypertension in Tibetan Adult Population","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2014-08","conditions":"Hypertension","enrollment":800},{"nctId":"NCT00935805","phase":"","title":"Glycemic And Blood Pressure Control In Type 2 Diabetes, In A Primary Care Unit: A Staged Management Strategy","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2006-07","conditions":"Diabetes Mellitus, Arterial Hypertension","enrollment":124},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Captopril,Hydrochlorothiazide","genericName":"Captopril,Hydrochlorothiazide","companyName":"West China Hospital","companyId":"west-china-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Captopril, a type of ACE inhibitor, is used to treat hypertension and has been studied in the context of COVID-19 severity and mortality. It is often combined with Hydrochlorothiazide, a diuretic, to manage blood pressure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}